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• Intranasal delivery of tranilast was enhanced by MGE and GMO liquid crystals 
• Biodistribution of administered LC formulations was visualized by micro-computed 
tomography tandem in vivo imaging systems 25 
• MGE and GMO formed liquid crystal structures with formulation characteristics 









Intranasal administration is poised as a competent method in delivering drugs to the 35 
brain, because the nasal route has a direct link with the central nervous system bypassing the 
formidable blood-brain barrier. C17-monoglycerol ester (MGE) and glyceryl monooleate 
(GMO) as liquid crystal (LC)-forming lipids possess desirable formulation characteristics as 
drug carriers for intranasally administered drugs. This study investigated the effect of LC 
formulations on the pharmacokinetics of tranilast (TL), a lipophilic model drug, and its 40 
distribution in the therapeutic target regions of the brain in rats. The anatomical biodistribution 
of LC formulations was monitored using micro-computed tomography tandem in vivo imaging 
systems. MGE and GMO effectively formed LC with suitable particle size, zeta potential, and 
viscosity supporting the delivery of TL to the brain. MGE and GMO LC formulations enhanced 
brain uptake by  10- to 12-fold and 2- to 2.4- fold, respectively, compared with TL solution. 45 
The olfactory bulb had the highest TL concentration and fluorescent signals among all the brain 
regions, indicating a direct nose-to-brain delivery pathway of LC formulations. LC-forming 
lipids, MGE and GMO, are potential biomaterials in formulations intended for intranasal 
administration. 
 50 
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 Delivering drugs to the central nervous system (CNS) in the management of acute and 60 
chronic neurodegenerative disorders remains an unmet clinical need owing to the blood-brain 
barrier, wherein numerous tight junctions and efflux transporters inhibit molecules from 
entering the brain, hence limiting therapies for many CNS diseases [1]. Oral routes of 
administration, the use of implanted medical devices, and intrathecal and 
intracerebroventricular injections have been used as methods to deliver drugs to the brain. 65 
Although these methods are used in clinical applications, they are associated with drawbacks 
such as invasiveness, low central bioavailability, and requiring clinical supervision during 
administration [2,3].  
Nasal drug administration is poised as a competent alternative to the currently available 
techniques, because drugs delivered by the intranasal route can be delivered directly to the 70 
brain and bypassing the blood-brain barrier. The direct anatomical link between the nasal cavity 
and the CNS makes it feasible to deliver many drugs via this route. Several studies have 
established that drugs reach the CNS from the nasal cavity by direct transport along olfactory 
and trigeminal pathways [4-7]. In addition, the nasal route of administration usually results in 
higher bioavailability, thereby requiring lower doses to be administered due to rapid absorption 75 
without enzymatic degradation and, in turn, reduced toxicity. The nasal route is noninvasive, 
can be self-administered, and may be better received by patients resulting in improved 
compliance [8-10].  
Liquid crystal (LC) systems have received significant attention as carriers for the 
controlled release of drugs because their unique microstructures have a range of desirable 80 
characteristics [11]. LC phases in formulations are thermodynamically stable, biocompatible, 
and contain extremely large surface areas with the ability to incorporate numerous drugs 
independently of their solubilities [12,13]. Moreover, LC systems can spontaneously form 
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either lamellar, cubic, or hexagonal crystalline mesophases by adding biocompatible 
amphiphilic lipids, such as glyceryl monooleate (GMO) and C17 – monoglycerol ester (MGE), 85 
to an aqueous environment. LC systems formed by GMO and water have been extensively 
investigated about their ability to sustain the release of a wide range of drugs. The use of GMO 
in LC systems has been applied in various administration routes, comprising oral, transdermal, 
and ophthalmic delivery, but there have been no studies with regards to its usefulness for nose-
to-brain delivery [11,14].  90 
Tranilast (TL), a lipophilic molecule, was selected as a model drug for this study 
because its clinical uses have extended beyond bronchial asthma, atopic dermatitis and allergic 
conjunctivitis [15]. Several studies have demonstrated that TL suppresses inducible nitric oxide 
synthase and activity by interferon-. Hence, the potential for TL in treating various CNS 
conditions associated with nitric oxide production including multiple sclerosis, cerebral 95 
ischemia, and Alzheimer’s disease is underway [16,17]. Additionally, the purported 
applications of TL in the treatment of Alzheimer’s disease has been appropriately patented [18]. 
Therefore, the critical value of enhanced delivery of TL to the brain must be explored. 
In this study, we developed LC formulations of TL using a novel LC-forming lipid, 
GMO and MGE, intended to be administered intranasally. Previously, we reported that an 100 
MGE-based LC had an ideal size range and zeta potential suitable as a candidate drug carrier 
for intranasally administered drugs. MGE was selected as an LC-forming lipid for its stability 
and better drug absorption enhancement compared with other LC-forming lipids [19]. Our 
study aimed to establish the effect of LC formulations on the distribution of TL to specific 
brain regions after intranasal administration in rats. TL concentration has been quantified in 105 
therapeutic target regions (i.e., hippocampus, cortex) in the brain. Lastly, the biodistribution of 
LC formulations from the nose to the brain was verified using micro-computed tomography 
(µCT) tandem in vivo imaging systems.    
 5 
MATERIALS AND METHODS 
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Materials and animals 
 TL was purchased from Tokyo Chemical Industry Co. Ltd. (Tokyo, Japan). Pluronic 
F-127 was purchased from Sigma-Aldrich (St. Louis, MO., U.S.A.). C17-monoglycerol ester 
(MGE) and glyceryl monooleate (GMO) were provided by Farnex Inc. (Yokohama, Japan). A 
near-infrared fluorescent cyanine dye, 1,1’-dioctadecyltetramethylindotricarbocyanine iodide 115 
(DiR) was purchased from Thermo Fisher Scientific (Waltham, MA., U.S.A.). Ethanol (99.5%) 
and acetonitrile (99.8%) were purchased from Fujifilm Wako Chemical Corp. (Osaka, Japan). 
 Male Sprague Dawley rats  (7 weeks of age, body weight 230  10 g) were obtained 
from Sankyo Laboratory Service Corporation, Inc. (Tokyo, Japan). Animals were housed in a 
controlled environment (25C, 12 h light-dark cycle) with free access to food and water. Rats 120 
were anesthetized with three types of anesthesia (0.375 mg/kg medetomidine, 2.5 mg/kg 
butorphanol, and 2 mg/kg midazolam) by intraperitoneal route (i.p.) prior to experiments.  
 The animal experiment protocol was approved by the Animal Care and Use Committee 
of Josai University with the approval number JU18003.  
 125 
Preparation and characterization of LC formulations 
 The compositions of LC formulations prepared in this study are presented in Table 1. 
The selection of components and proportions of the formulations were based on our previous 
work on MGE LC formulations with slight modification [19]. GMO was melted at 80 C before 
use.  The components were combined and the resulting mixture was sonicated using a probe 130 
sonicator (VCX-750, Sonics & Materials, Inc., Newton, CT, U.S.A.) at an amplitude of 20% 
for 5 mins. TL in solution (TLC), which served as the control, was prepared by dissolving TL 
with a sufficient amount of phosphate-buffered saline (PBS) pH 7.4. 
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Measurement of vesicle size, polydispersity index, and zeta potential 135 
 The vesicle size, polydispersity index (PDI), and zeta potential of the prepared LC 
formulations (TLM, TLME, TLG, TLGE) were determined using a dynamic light scattering Nano-
ZS ZEN3600 Zetasizer (Malvern Instruments Ltd., Worcestershire, U.K.). Formulations were 
diluted with purified water and shaken using a vortex mixer prior to measurement. 
Measurement of vesicle size, PDI, and zeta potential was done in triplicate at room temperature.  140 
 
Measurement of viscosity  
 The viscosity of LC formulations was determined using a viscometer (Toki Sangyo Co., 
Ltd, Tokyo, Japan) with a sensitivity range of 0.3 – 10,000 mPas and with an accuracy of 1% 
relative error.   145 
 
Small Angle X-ray scattering (SAXS) analysis 
 The prepared LC formulations were subjected to small angle X-ray scattering (SAXS) 
measurement using a Nano-viewer (Rigaku, Akishima Tokyo, Japan) with a Pilatus 100K/RL 
2D detector. The X-ray source was Cu K radiation with a wavelength of 1.54 Å and operating 150 
at 45 kV and 110 mA. The sample-to-detector distance was set at 375 nm. The individual 
sample was placed in a vacuum – resistant glass capillary cell and exposed at 25C for 1 h. The 
SAXS pattern obtained was plotted against the scattering vector length, q = (4/) sin (/2), 
where  is the scattering angle. The scattering intensity was normalized using the decayed 
direct beam intensity.  155 
 
Entrapment efficiency  
 7 
 In the measurement of entrapment efficiency, LC formulations were centrifuged at 
15,000 rpm for 15 min at 4C. An aliquot of the resulting supernatant was withdrawn and 
diluted with ten-fold acetonitrile and quantified using liquid chromatography–tandem  mass 160 






where EE, TLtotal, TLfree are entrapment efficiency, total TL concentration in formulation, and 
concentration of TL in the supernatant, respectively.  165 
 
In vitro drug release from the LC formulations 
 In vitro drug release of the formulations was evaluated using a dialysis membrane (MW 
cut-off; 2,000 – 14,000 Da, Sanko Junyaku Co., Tokyo, Japan) previously hydrated and set on 
a side-by-side diffusion cell (effective diffusion area: 0.95 cm2). PBS was filled into the 170 
receiver chamber. The receiver chamber was thermostatically maintained at 37C. LC 
formulations (3.0 mL) were applied to the donor cell to commence the release experiment. 
Sampling was performed by withdrawal of an aliquot (500 L) at pre-determined time points. 
An equal volume of PBS was added to the receiver chamber to keep the volume constant 
throughout the experiment.  175 
 
Tissue distribution studies of TL formulations 
 Rats were randomly divided into five groups. TLM, TLME, TLG, TLGE, and TLC (0.5 
mg/kg) were intranasally administered to the first, second, third, fourth and fifth groups, 
respectively. Ten microliters of either LC formulation or TLC was administered dropwise using 180 
a micropipette (Eppendorf Reference 2, Eppendorf AG, Hamburg, Germany) inserted (0.5 
 8 
cm) into each nostril with an interval of 60 s. Rats were kept in supine position throughout the 
experiment. A separate group of rats was allocated for intravenous administration, the tranilast 
solution (0.5 mg/kg) was administered through the tail vein.  
 At predetermined time points (0.17, 0.5, 1, 2, 4, 8 h), approximately 200 L of blood 185 
was withdrawn from the jugular vein and directly transferred into heparinized tubes and 
immediately centrifuged (15,000 rpm; 10 min; 4C) to obtain plasma. After this, the same 
volume of normal saline solution was infused via the tail vein to circumvent alterations in the 
volume of distribution. After blood collection at 2, 4, and 8 h, rats were deeply anesthetized 
with three types of anesthesia i.p. as abovementioned and transcardially perfused with cold 190 
PBS to avoid blood from contaminating the brain. The whole brain was isolated and dissected 
on ice into specific regions (olfactory bulb, cortex, brainstem, cerebellum, midbrain, 
hippocampus). The spinal cord was also collected. The collected brain samples were weighed 
then reduced in size using scissors, and 0.5 mL of acetonitrile was added prior to 
homogenization at 12,000 rpm and 4C for 5 min using a homogenizer (Polytron PT 1200 E, 195 
Kinematica AG, Littaue-Lucerne, Switzerland). The brain homogenates were then centrifuged 
at 15,000 rpm and 4C for 5 min. The plasma and brain samples were kept at -30C until 
analysis.  
 The peak plasma concentration (Cmax) was determined directly from plasma or brain 
concentration-time curves. The area under the plasma or brain concentration-time curve (AUC0-200 
8) was calculated using trapezoidal rule [20-22]. Drug targeting efficiency percentage (DTE) 
and nose-to-brain direct transport percentage (%DTP) were calculated according to previous 




















) ∙  𝑃𝑖𝑛      Eq. 3 
where Bx is the brain AUC fraction contributed by the systemic circulation through the Blood-
Brain Barrier following intranasal administration, Bin is the brain AUC over time following 
intranasal administration, Piv is the blood AUC over time following intravenous administration, 210 
and Pin is the blood AUC over time following intranasal administration [24].   
 
Sample preparation and quantification of TL using LC-MS/MS 
Supernatant (50 L) from plasma or brain homogenates or samples from the in vitro 
release experiment were mixed with an equal amount of acetonitrile and centrifuged at 4C for 215 
5 min. The resulting supernatant (10 L) was injected into an LC/MS/MS system for the 
quantification of TL. The LC/MS/MS systems consisted of a system controller (CBM-20A; 
Shimadzu Corporation, Kyoto, Japan), pump (LC-20AD; Shimadzu), auto-sampler (SIL-
20ACHT; Shimadzu), column oven (CTO-20A; Shimadzu), detector (4000QTRAP; AB Sciex; 
Tokyo, Japan), and analysis software (Analyst version 1.4.2; Shimadzu). The column (Shodex 220 
ODP2HPG-2A 2.0 mm x 10 mm, Showa Denko Inc; Tokyo, Japan) was kept at 40C. The 
mobile phase used was acetonitrile:0.05% formic acid containing 5 mM ammonium acetate 
(80:20). The flow rate was maintained at 0.2 mL/min. Mass spectrometric quantification was 
carried out in the multiple reaction monitoring (MRM) mode, monitoring transition ions of m/z 
328.0 to m/z 191.2 with collision energy of 36 eV. Calibration was carried out with six different 225 
concentrations within a range of 1–1000 ng/mL with a correlation coefficient of 0.9999.  
 
In vivo biodistribution studies of LC formulations using combined in vivo imaging system 
and µCT. 
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 MGE and GMO LC formulations were labeled with 0.2 mM DiR, a highly fluorescent 230 
dye when incorporated into lipids. DiR-labeled MGE (DiRM, DiRME) and GMO (DiRG, DiRGE) 
LC formulations were prepared using the quantities described in Table 1 without TL. DiR 
solution (DiRS) (0.2 mM) was prepared by diluting DiR ethanol solution (10 mM) with a 
sufficient amount of water. 
 Sprague Dawley rats were anesthetized and divided into five groups; DiRM, DiRME, 235 
DiRG, DiRGE, DiRS. Before administration, rats were subjected to X-ray µCT imaging using 
CosmoScan GX II system (Rigaku Corp., Akishima, Tokyo, Japan). Cranial bone images of 
rats were obtained using the following parameters: 90 kV of X-ray tube voltage, 88 μA of X-
ray tube current. Then, DiRM, DiRME, DiRG, DiRGE, DiRS were administrated intranasally to 
the assigned rats identically to the abovementioned procedure in the pharmacokinetics study. 240 
After administration, in vivo fluorescent images of rats were obtained at 0, 15, 30, 60 and 120 
min using the IVIS® Spectrum in vivo imaging system (PerkinElmer® Ltd., Waltham, MA, 
USA). To visualize the fluorescence signals of formulations in 3D anatomical context, 
fluorescence signals were co-registered with the anatomical μCT images using Multi-Modality 
Module Software (PerkinElmer® Ltd., Waltham, MA, USA).  245 
At 120 min post-intranasal administration, rats were sacrificed and the whole brain was 
carefully excised to avoid contamination. Ex vivo fluorescent imaging of the whole brain was 
conducted with the IVIS® Spectrum in vivo imaging system.  The following conditions were 
used for image acquisition:  745 nm excitation and 800 nm emission filters, auto exposure time 
and F/Stop = 2. The fluorescence images were analyzed by Living Image® 4.7.2 software 250 
(PerkinElmer® Ltd., Waltham, MA, USA). All experiments were conducted in three trials.  
 
Statistical analysis  
 11 
Statistical analyses were performed using Student’s t-test (p < 0.05). All data were 




Characterization of LC formulations 
 TLM and TLME formulations were opaque white dispersion without visible aggregates, 260 
whereas TLG and TLGE  formulations were viscous, pale yellow dispersions without visible 
aggregates, and all formulations were stable throughout the experiment. TLC was a clear 
colorless solution. Table 2 shows the mean vesicle size, PDI, zeta potential, viscosity, and 
entrapment efficiency of the prepared formulations. PDI values of MGE and GMO-based 
formulations indicated homogenous particle size distribution. Negative zeta potential is good 265 
for fine dispersion of the formulation. Addition of ethanol (TLM to TLME, TLG to TLGE) 
markedly increased the viscosity of the formulations. Entrapment efficiency of MGE- and 
GMO-based formulations exhibited good incorporation of TL in the LC structure. The phase 
structure of TL formulations was evaluated using SAXS and X-ray diffraction profiles showed 
typical peaks reflection patterns at nearly 1, √3 , and  √4  for TLM suggesting an inverse 270 
hexagonal type of LC (Fig. 1). TLME revealed peaks reflection patterns at √2 , √3 , √4 , 
√6, √8, √9 suggesting a bicontinuous cubic (Pn3m) type of LC. TLG showed peaks reflection 
patterns at √2 , √4 , √6  indicating a bicontinuous cubic (Im3m) LC, whereas TLGE had 
unverified reflection patterns. DiR-labeled LC formulations had identical peak reflection 
patterns with their respective TL LC formulations (data not shown). Particle size, PDI, and zeta 275 
potential of DiR-labeled LC formulations had indistinguishable variances with their respective 
TL LC formulations (data not shown).  
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Drug release profile of LC formulations 
 Figure 2 shows the release profile of TL from the LC formulations. The cumulative 280 
amount of TL released over 8 h from TLM, TLME, TLG and TLGE were 389.75  23.06 µg/cm
2, 
547.70  12.33 µg/cm2, 185.24  9.39 µg/cm2, 268.56  22.41 µg/cm2, respectively. This 
corresponds to a 2-fold higher release rates in MGE formulations when compared with GMO 
formulations. For both MGE and GMO formulations, addition of ethanol increased the release 
rate of TL.  285 
 
TL distribution in plasma and whole brain  
 Brain uptake of TL following intranasal administration on Sprague Dawley rats was 
observed for a duration of 8 h. Figure 3A and B show the TL concentration in plasma and the 
whole brain, respectively, following intranasal administration. Table 3 presents the 290 
pharmacokinetic parameters. TLM and TLME formulations exhibited a sustained TL 
concentration profile in the brain (Fig. 3B). TLME  formulations had AUC(0-8) values of 94.5 
and 114 ngh/mL in the whole brain, which corresponded to 10- to 12-fold higher TL 
concentration compared with TLC. TLME showed the highest Cmax in the brain. Mean residence 
time of TL from LC formulations in the brain ranged from 4 to 6 h corresponding to 2- to 3-295 
fold higher residence time in the brain than in plasma.  
  
TL distribution in brain regions 
Figure 4 shows the TL distribution in different regions of the brain following intranasal 
administration. All brain regions showed uptake of TL at 2 h, the first collection point. 300 
Formulations containing MGE and GMO exhibited increasing TL concentrations in different 
brain regions over time, but TLC showed a decreasing trend. An apparent selective distribution 
of TL from LC formulations to brain regions was seen from 4 to 8 h. Among the brain regions, 
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the olfactory bulb showed the highest TL concentration of 76.3 ng/g and 18.2 ng/g at 2 h 
following the intranasal administration of TLM and TLME, respectively. TLM showed a 305 
decreasing TL concentration in the olfactory bulb over time whereas TL concentrations in the 
hippocampus increased over time. In addition, higher TL concentrations at 8 h were observed 
in the hippocampus and spinal cord for MGE LC formulations. Calculated %DTE and %DTP 
are presented in Table 3.  
 310 
In vivo biodistribution studies of LC formulations 
Figure 5 shows in vivo fluorescent images of DiR-labeled LC formulations combined 
with µCT. The combination in vivo imaging system and µCT imaging allowed the visualization 
and monitoring of the distribution of formulations in a 3D anatomical context. A fluorescent 
dye, DiR, was incorporated to lipid-based LC formulations to understand the disposition of 315 
administered formulations from the nasal cavity to the brain. The movement and location of 
fluorescence signals in DiRM and DiRME LC formulations were traced from the administration 
site to the adjacent regions of the olfactory region, and finally in the olfactory bulb. DiRG and 
DiRGE LC formulation had strong fluorescence that remained stationary in the nasal cavity (see 
Fig. 5B). DiR solution (DiRS)exhibited rapid elimination from the nasal cavity and generated 320 
low fluorescence signals. Moreover, slice images of rat cranium in the lateral direction (Fig. 
5B) revealed the localization of the fluorescence. Ex vivo images of the whole brain had strong 
fluorescence in the olfactory bulb and brain stem from DiRM but detectable fluorescence in the 
olfactory bulb was only found from DiRME LC formulation at 120 mins post-administration 




The usefulness of MGE- and GMO-based LC as nanocarriers in enhancing the delivery 
of TL into the brain and its specific regions after intranasal administration was investigated in 
this study. TL concentrations in specific brain regions were determined instead of the whole 330 
brain alone in an attempt to understand the distribution pathway of TL from LC formulations. 
In addition, MGE- and GMO-based formulations containing ethanol were also prepared to 
clarify the influence of ethanol on the properties of LC systems and its impact on nose-to-brain 
delivery, because the mixture of water and ethanol is a common solvent in dissolving lipophilic 
drugs, such as TL, in pharmaceuticals.  335 
MGE and GMO lipids with TL (TLM and TLG) formed an H2 inverted hexagonal phase 
LC and Im3M body-centered cubic phase LC, respectively, whereas the addition of ethanol to 
MGE (TLME) formed a Pn3m bicontinuous double-diamond cubic structure, suggesting that 
ethanol possibly modulates the transitions in LC structures (see Fig. 1). An aqueous dispersion 
of TL consisting of nanoparticles with an internal reversed hexagonal structure, hexosomes, or 340 
reversed internal bicontinuous cubic phase, cubosomes, were successfully prepared in this 
study. Hexosomes and cubosomes function as versatile platforms for drug delivery owing to  
their capacity to incorporate drugs independently of their solubilities and their large surface 
areas to interact with biological membranes [25].  
MGE (TLM, TLME) and GMO (TLG, TLGE) LC formulations were characterized in 345 
terms of particle size, PDI, zeta potential, viscosity, and entrapment efficiency (Table 2). The 
particle size of prepared LC formulations conformed with the ideal nanocarrier size of 150 – 
400 nm, which can efficiently deliver drug payload into the brain [5, 9, 10, 26]. PDI values 
indicated a homogenous particle size distribution in the formulations. The zeta potential of the 
prepared LC formulations had strong negative values, suggesting predominance of repulsive 350 
forces at the surface of the LC, which resisted aggregation of particles and yielded better 
stability of the formulation [27,28]. Viscosity values of the LC formulations were significantly 
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different from the control. Formulations containing GMO and ethanol had higher viscosities. 
MGE and GMO formulations had higher entrapment efficiency by 1 to 1.5-fold compared with 
their ethanol-containing formulations, which might support their function as a carrier of TL 355 
from nose to brain, and the ability of the LC formulation to release TL was confirmed in our 
in vitro release studies. Bicontinuous LC structures (TLME, TLG) had higher drug release rates 
compared with the inverse hexagonal LC (TLM) structure, which was possibly related to the 
differences in the internal structures of the LC involved. In addition, the entrapment efficiency 
and in vitro release data indicated that sufficient concentrations of TL were detected in the 360 
brain despite lower volumes of the formulation (10 L/nostril) administered intranasally than 
previous reports (25 – 60 L/nostril) [20,29].  
In vivo studies on the nose-to-brain delivery of TL were implemented to understand 
how LC formulations affect the distribution of TL in the brain. TL in solution (TLC) exhibited  
AUC values of 189 ng·h/mL in the plasma and 9.55 ng·h/mL in the brain, which corresponded 365 
to a 20-fold higher plasma concentration, indicating that TL rapidly entered the systemic 
circulation after intranasal administration but had poor localization in the brain (Table 3). On 
the other hand, MGE and GMO LC formulations rendered TL with higher transport efficiency 
in the brain which corresponds to 10- to 12-fold and 2- to 2.4- fold higher brain uptake, 
respectively, when compared with TLC (Table 3). TL concentrations in the brain were higher 370 
compared to plasma for TLM, while otherwise was observed for TLME. TLG and TLGE 
formulations yielded low concentrations of TL in the brain and plasma, which was  attributable 
to their high viscosities. GMO-based LC formulations had 2- to 3-fold higher viscosity than 
MGE-based LC formulations. In addition, viscosity may have contributed to the delayed time 
to reach peak concentration in the brain, as observed in GMO-based LC formulations. Of note, 375 
MGE-based LC formulations showed faster systemic and brain transport than GMO-based 
formulations wherein differences in the morphology of the LC may explain this finding. 
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Furthermore, LC formulations exhibited longer residence time in the brain than TLC, signifying 
a slow absorption rate and subsequently a slow elimination process, enabling TL accumulation 
in the brain. In a previous study, oral administration of TL was reported to have a low brain 380 
tissue-to-plasma concentration ratio (Kp) of 0.38 [30]. In our study, a lower Kp value was 
observed in TLC (0.13) after intranasal administration. However, Kp values of intranasally 
administered LC formulations were 0.46 – 3.4 (Table 3), corresponding to 1.2- to 9-fold higher 
TL concentrations in the brain than the oral route. The intranasal route of administration proved 
to be superior over oral routes of administration in the delivery of TL to the brain.  385 
Findings from the biodistribution studies revealed that GMO-based formulations (DiRG 
and DiRGE) remained in contact with the nasal cavity over a period of 2 h with sustained 
fluorescence intensity, indicating that the drug remained at the application site (Fig. 5A). On 
the other hand, the DiRM and DiRME formulations were observed to diffuse gradually from the 
nasal cavity into the olfactory region, suggesting the controlled release of MGE LC 390 
formulations. DiRS transited into the pharynx rapidly indicating fast elimination of the solution 
from the application site (Fig. 5A, B). Co-registered fluorescence with X-ray and µCT images 
of the cranium confirmed the localization of DiR in the rostral sections of the brain from MGE-
based LC formulations. Ex vivo brain images of rats administered DiR-labeled MGE LC 
formulations had higher fluorescence than their ethanol counterparts (Fig. 5C). This affirmed 395 
our data on TL tissue distribution for TLM where higher brain targeting and a lower systemic 
absorption were observed compared with TLME. In addition, the differences in the LC 
structures possibly influenced the localization and extent of biodistribution of LC formulations 
where DiRM (inverse hexagonal) and DiRME (bicontinuous cubic, Im3m) showed  higher brain 
penetration.  400 
Formulation design plays an important role in targeted drug delivery into specific 
regions of the brain (i.e. hippocampus and cortex in Alzheimer’s disease; midbrain in 
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Parkinson’s disease) in mitigating neurodegenerative diseases. TL concentrations from MGE-
based LC formulations in different brain regions were significantly higher compared with the 
GMO-based LC formulations and control at 8 h (Fig. 3B). TL was detected in brain regions of 405 
therapeutic interest, particularly the midbrain, cortex, and hippocampus (Fig. 4). Among the 
regions of the brain, the olfactory bulb had the highest TL concentration from MGE-based LC 
formulations (Fig. 4). In addition, ex vivo brain images of DiRM and DiRME showed strong 
fluorescence localized in the olfactory bulb and brain stem (Fig. 5C). This evidence confirmed 
the direct pathway to support nose-to-brain delivery of drugs by LC formulations.  410 
Transport of drugs into the brain from the olfactory region of the nasal cavity is 
supported by two known pathways, the olfactory and trigeminal pathways. The olfactory 
ensheathing cells and neural fibroblasts in the olfactory region are structures continuous with 
the meninges covering the brain, and thus capable of transporting drugs directly into the brain 
following intranasal administration [31]. TL concentration in whole brain for TLM formulation 415 
peaked at 2 h, and dissection of brain regions revealed that TL concentrations in olfactory bulb 
peaked at 2 h as well (Fig. 3). In addition, DiRM exhibited strong fluorescence in the olfactory 
bulb, which was confirmed in the biodistribution studies and ex vivo brain images at 2 h (Fig. 
4). This suggested that a direct nose-to-brain delivery of TL exists via the olfactory pathway 
for the TLM formulation. TLM is a less viscous formulation that tended to flow freely and 420 
diffused sufficiently to cover a large surface area of the olfactory region. On the other hand, 
the high concentrations of TL found in plasma (Fig. 2A) and the brain stem (Fig. 3) presented 
a different distribution pathway for TL from TLME, with the respiratory epithelium possibly 
influencing its transport. Moreover, the high viscosity of the TLME formulation (Table 2) may 
facilitate prolonged contact with the lateral walls of the nasal cavity of the anterior respiratory 425 
epithelium instead of the olfactory region, which is located at the far superior aspect of the 
nasal cavity. The large and highly vascularized surface area of the respiratory epithelium, a 
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known absorption site of drugs, could have been the gateway for the systemic absorption of 
TL from TLME. In the case of TLME formulation, TL was solubilized in ethanol effectively and 
the presence of MGE acting as a membrane permeation enhancer may have facilitated the 430 
absorption of TL through the respiratory epithelium. Moreover, trigeminal nerves (maxillary 
branch), originating from the brain stem, innervate the respiratory epithelium and may facilitate 
the transport of TL into the brain via the trigeminal pathway. It must be noted that the olfactory 
pathway delivers drug to the rostral (front) sections of the brain, whereas the trigeminal 
pathway delivers to both rostral and caudal (back) sections of the brain, making it difficult to 435 
account for which pathway facilitated drug transport into the rostral section [26]. Both MGE-
based LC formulations showed high brain uptake. However, this phenomenon can be explained 
by two different pathways of absorption. The Kp value of TLM  was 2.8, 2.5, and 3.4 at 2, 4 
and 8 h, respectively, whereas TLME had Kp values of 0.2, 0.3, and 0.7, respectively. The 
calculated Kp value of TLME at 2 h was closely related to the Kp value obtained for TLC (0.13), 440 
indicating that the systemic circulation contributed to TL brain uptake in the first few hours, 
and a direct nose-to-brain route contributed to TL in the brain at a later time, as shown by the 
increasing Kp values over time.  TLM had high Kp values maintained over time, with  a 
predominantly  direct nose-to-brain migration proposed for TLM, as indicated by its higher TL 
concentration in brain than in plasma. Moreover, %DTP supports this finding wherein 73.9% 445 
of TL from TLM at 8 h were attributed to a direct nose-to-brain pathway (Table 3).  TL 
concentration in the brain for TLME  had contributions from direct nose-to brain migration as 
well as TL penetrating the brain via systemic circulation, as indicated by the higher plasma 
concentration obtained for TLME (Fig.3A). Further investigations to clarify the distribution 
pathway of LC formulations in delivering drugs to the brain are needed. 450 
Our previous works on MGE-based liquid crystals injectable formulations in in vivo 
experiments in rats demonstrated no severe toxicities (no weight loss, no respiratory failure 
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and no inflammation at the administration site) while its antiadhesion formulation in a rat 
peritoneal adhesion model was found to be well tolerated with both studies spanning weeks of 
observation [32,33]. Isoprenoid-type compounds are metabolized by the liver and excreted by 455 
the kidney and intestinal tract. It is potentially predictable that MGE follows this particular 
metabolic pathway [33]. On the other hand, GMO is a nontoxic, biodegradable, and 
biocompatible material and is listed in the FDA's Inactive Ingredients Guide [34]. However, 
further studies are needed to be performed for better understanding of local (i.e., nasal 
ciliotoxicity studies), systemic toxicity and biocompatibility of intranasally administered liquid 460 
crystal formulations.  
Formulation characteristics of MGE- and GMO-based LC formulations administered 
intranasally supported the delivery of drugs into the brain. This is the first study to demonstrate 
the usefulness of LC formulations in enhancing TL delivery into the brain following intranasal 
administration. In addition, this is a pioneering work utilizing the combined methods of an in 465 
vivo imaging system and µCT in visualizing the biodistribution of LC formulations to identify 
the anatomical localization of drugs. Although this is a putative evidence on the LC-mediated 
delivery of drugs into the brain by intranasal administration, further investigations focusing on 
optimizing the effects of LC-based drug carriers, understanding formulation mechanisms, and 
the dose needed to exhibit pharmacologic actions in brain disease models are recommended.  470 
 
CONCLUSION 
MGE and GMO effectively formed LCs with suitable formulation characteristics 
supporting the brain uptake of lipophilic drugs. Intranasal administration of LC formulations 
enhanced the delivery of TL into the brain and distribution to brain regions. The olfactory bulb 475 
consistently had the highest TL concentration and fluorescence signals among all the brain 
regions, indicating a direct nose-to-brain delivery pathway for the LC formulations. GMO-
 20 
based LC formulations demonstrated the ability to sustain contact with the nasal cavity. MGE-
based LC formulations can diffuse deep within the olfactory region and exhibit higher drug 
transport into the brain. LC-forming lipids, MGE and GMO, are potential biomaterials in 480 
formulations intended for intranasal administration. Biodistribution properties of intranasally 
administered LC formulations from the nasal cavity into the rostral section of the brain have 
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Figure 2. In vitro release profile of tranilast formulations. TLM (⬦), TLME (⬥), TLG (○), TLGE 
(●). Each value represents the mean  S.E. (n= 3 – 4). Significant difference (*p ≤ 0.05) 
between TLME and TLG or TLGE.  
 630 
 
Figure 3. Concentration of tranilast in plasma (A) and whole brain (B). TLM (⬦), TLME (⬥), 
TLG (○), TLGE (●),TLC (▲). Each value represents the mean  S.E. (n= 3 – 4). Significant 














































































































































































































































































































Figure 4. Concentration of tranilast in brain regions. TLM (■), TLME (■), TLG (□), TLGE (░), 
TLC (▩). Each value represents the mean  S.E. (n= 3 – 4). Significant difference (p ≤ 0.05) 
between *TLM and TLG, TLGE, or TLC; 




















































































































































































































































































Figure 5. Biodistribution of LC formulations by in vivo fluorescent/µCT imaging. (A) in vivo 655 
fluorescent signals co-registered with X-ray and micro-computed tomography images (µCT); 
(B) Slice images in the lateral direction at 120 min post-administration; (C) ex vivo fluorescent 
images of whole brain at 120 min post-administration. Representative images are presented in 




































































Table 1. Composition of nasal formulations 
Components (%) TLM TLME TLG TLGE TLC 
Tranilast 0.5 0.5 0.5 0.5 0.5 
Monoglycerol ester (MGE) 20 20 − − − 
Glyceryl monooleate (GMO) − − 20 20 − 
Pluronic F-127  5 5 5 5 − 
Ethanol − 5 − 5 − 
Purified water 74.5 69.5 74.5 69.5 − 
PBS (pH 7.4) − − − − 99.5 
Total  100 100 100 100 100 
 675 
 










TLM 300  0.65 0.38  0.28 -24.1  0.23 334.6 90.5  0.46 
TLME 256  0.39 0.40  0.13 -35.0  0.19 913.7 85.8  0.52 
TLG 179  0.53 0.13  0.93 -15.5  0.16 1120.5 70.6  0.45 
TLGE 404  0.46 0.33  0.88 -16.1  0.19 2237.2 53.8  1.02 
 
 























*Kp %DTE %DTP 
TLM 33.9  7.03 71.4  11.4 - - 19.4  1.50 94.5  3.68 - - 3.4 384 73.9 
TLME 346  48.6 725  33.1 - - 19.4  1.07 114  5.92 - - 0.66 45.6 -119 
TLG 61.0  12.0 142  9.13 - - 8.84  3.63 22.7  6.41 - - 1.09 46.3 -115 
TLGE 10.0  1.71 56.4  8.13 - - 2.75  0.06 15.5  2.73 - - 0.46 79.6 -25.5 
TLC 181  31.3 189   16.2 1064.3  5.23 1018.6  8.19 3.46  0.31 9.55  2.17 116.5  4.31 351.5  4.16 0.13 14.6 -582 
i.n.: intranasal; i.v.: intravenous; *tissue-to-plasma concentration ratio (whole brain TL concentration/plasma TL concentration) at 8 h.  
